Page 2 - Nasdaq Angn News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq angn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Angn Today - Breaking & Trending Today

Angion Biomedica Corp. (NASDAQ:ANGN) Sees Large Growth in Short Interest

Angion Biomedica Corp. (NASDAQ:ANGN – Get Rating) was the recipient of a significant growth in short interest in the month of April. As of April 30th, there was short interest totalling 649,500 shares, a growth of 20.1% from the April 15th total of 540,800 shares. Approximately 3.5% of the company’s shares are sold short. Based […] ....

Angion Biomedica , Zacks Investment Research , Cm Management , Renaissance Technologies , Angion Biomedica Corp , Patriot Financial Group Insurance Agency , Walleye Capital , Angion Biomedica Company Profile Get Rating , Valeo Financial Advisors , Get Rating , Financial Group Insurance Agency , Financial Advisors , Investment Research , Biomedica Company Profile , Biomedica Corp , Nasdaq Angn ,

Angion Announces Phase 1b Trial of ANG-3070 in Patients

The FDA has accepted an IND application supporting clinical development of ANG-3070 in IPF Phase 1b trial to be initiated to gather tolerability,. ....

John Neylan , Drug Administration , Angion Biomedica Corp , Investigational New Drug , Discoidin Domain Receptors , Executive Vice President , Chief Medical , Nasdaq Angn , Ngion Biomedica Corp , Idiopathic Pulmonary Fibrosis , Ung Disease , Clinical Trial ,

Angion Biomedica (NASDAQ:ANGN) Releases Quarterly Earnings Results, Beats Estimates By $1.17 EPS

Angion Biomedica (NASDAQ:ANGN – Get Rating) issued its quarterly earnings results on Wednesday. The company reported $0.58 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.59) by $1.17, Fidelity Earnings reports. The business had revenue of $25.94 million for the quarter, compared to analyst estimates of $1.98 million. Angion Biomedica had a negative […] ....

Angion Biomedica , Morgan Stanley , Zacks Investment Research , Deutsche Bank , Millennium Management , Angion Biomedica Corp , Valeo Financial Advisors , Get Rating , Fidelity Earnings , Street Corp , Financial Advisors , Investment Research , Biomedica Corp , Nasdaq Angn ,